Intelligence · Clinical Pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs: 1,344

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

FPA144

Prime Medicine

Advanced Solid Tumors

phase 1 small molecule completed

1 trial
FPA150

Prime Medicine

Breast Cancer

phase 1 mab terminated

1 trial
FPT155

Prime Medicine

Advanced Solid Tumors

phase 1 mab terminated

1 trial
FT500

Zafatek

Advanced Solid Tumors

phase 1 small molecule completed

1 trial
FT516

Zafatek

Solid Tumor, Adult

phase 1 small molecule terminated

1 trial
FT516

Zafatek

Acute Myelogenous Leukemia

phase 1 small molecule terminated

1 trial
FT522

Zafatek

Relapsed/Refractory B-Cell Lymphoma

phase 1 small molecule completed

1 trial
FT536

Zafatek

Non Small Cell Lung Cancer

phase 1 small molecule terminated

1 trial
FT538

Zafatek

Acute Myeloid Leukemia

phase 1 small molecule terminated

1 trial
FT538

Zafatek

Solid Tumor, Adult

phase 1 small molecule terminated

1 trial
FT596

Zafatek

Lymphoma, B-Cell

phase 1 small molecule terminated

1 trial
FT596

Zafatek

Diffuse Large B Cell Lymphoma

phase 1 small molecule terminated

1 trial
FT819

Zafatek

Lymphoma, B-Cell

phase 1 small molecule active

1 trial
FT825

Zafatek

Advanced Solid Tumor

phase 1 small molecule active

1 trial
FT836

Zafatek

Non-Small Cell Lung Cancer

phase 1 small molecule active

1 trial
Fast Dual CAR-T Injection

Xiyuan Hospital of China Academy of Chinese Medical Sciences

B-cell Lymphoma

phase 1 mab terminated

1 trial
First in human pilot study to assess the safety and efficacy of dendritic cells loaded with frameshift derived neopeptides for the prevention of cancer in Lynch Syndrome carriers

The George Institute

Lynch Syndrome

phase 1 other active

1 trial
First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma

The George Institute

Relapsed/refractory B-cell aggressive lymphoma

phase 1 other active

1 trial
First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

GlaxoSmithKline

Neoplasms

phase 1 other active

1 trial
First-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes

Advanced Accelerator Applications

Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes, Ineligible for Intensiveor New Generation Targeted Therapy

phase 1 other active

1 trial
First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer

OnKure Therapeutics

Advanced Solid Tumors, Advanced Breast Cancer

phase 1 other active

1 trial
First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

Daiichi Sankyo

Advanced Solid Tumors

phase 1 other active

1 trial
First-in-Human trial of DS9051b in participants with advanced solid tumors

Daiichi Sankyo

Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Castration-resistant Prostate Cancer (CRPC)

phase 1 other active

1 trial
First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors

Daiichi Sankyo

Advanced Solid Tumors

phase 1 other active

1 trial
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

Genmab A/S

Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

phase 1 other active

1 trial
First-in-human Study to Test Safety and Anti-tumor Activity of a Novel Drug for Patients with Advanced Solid Tumor Harboring Genetic Alterations in MET

Turn Therapeutics

Phase 1: Advanced solid tumors harboring genetic alterations in MET

phase 1 other active

1 trial
First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors

Daiichi Sankyo

Advanced Solid Tumor

phase 1 other active

1 trial
First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)

Bayer Australia Ltd

Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expression

phase 1 other active

1 trial
First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer (ES SCLC) (DeLLphi-303)

Amgen

Extensive Stage Small cell lung cancer (ES-SCLC)

phase 1 other active

1 trial
Follicle Stimulating Hormone Receptor T Cells

Anixa Biosciences Inc

Ovarian Cancer

phase 1 small molecule active

1 trial
Fostamatinib 100 mg bid and Paclitaxel

RIGEL PHARMACEUTICALS INC

Ovarian Cancer

phase 1 small molecule completed

1 trial
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)

RIGEL PHARMACEUTICALS INC

Pancreatic Ductal Adenocarcinoma (PDAC)

phase 1 other active

1 trial
Furmonertinib

ArriVent BioPharma

Non-Small Cell Lung Cancer (NSCLC)

phase 1 small molecule active

1 trial
G207

BRIGHT MINDS BIOSCIENCES INC.

Supratentorial Neoplasms, Malignant

phase 1 mab completed

1 trial
GB-4362

Generate Biomedicines

Advanced Urothelial Cancer

phase 1 small molecule active

1 trial
GB-5267 - IV only

Generate Biomedicines

Platinum-resistant Ovarian Cancer

phase 1 mab active

1 trial
GC4419

Galera Therapeutics

Squamous Cell Carcinoma of the Oral Cavity

phase 1 small molecule completed

1 trial
GCAR1

Chongqing Precision Biotech Co., Ltd

Sarcoma

phase 1 mab active

1 trial
GCC2005

Artiva Biotherapeutics

Lymphoma, T-Cell

phase 1 small molecule active

1 trial
GDC-0084

KAZIA THERAPEUTICS LTD

Brain and Central Nervous System Tumors

phase 1 small molecule completed

1 trial
GEN1042

Genmab A/S

Malignant Solid Tumor

phase 1 mab active

1 trial
GK01 Injection

The First People's Hospital of Lianyungang

Advanced Solid Tumors

phase 1 small molecule active

1 trial
GLA-SE

Lxo Ireland Designated Activity Company

Merkel Cell Carcinoma

phase 1 mab completed

1 trial
GLPG0187

Lakefront Biotherapeutics NV

Solid Tumors

phase 1 small molecule completed

1 trial
GME751

Sandoz Pty Ltd

Melanoma

phase 1 small molecule active

1 trial
GMX1777

Teva Pharma GmbH

Solid Tumors and Lymphomas

phase 1 small molecule terminated

1 trial
GPC3 and/or TGFβ targeting CAR-T cells

The First People's Hospital of Lianyungang

Hepatocellular Carcinoma

phase 1 mab active

1 trial
GPC3-CAR-T cells

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Hepatocellular Carcinoma

phase 1 mab on hold

1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,344 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Quick answer

Top sponsors

FPA144

FPA150

FPT155

FT500

FT516

FT516

FT522

FT536

FT538

FT538

FT596

FT596

FT819

FT825

FT836

Fast Dual CAR-T Injection

First in human pilot study to assess the safety and efficacy of dendritic cells loaded with frameshift derived neopeptides for the prevention of cancer in Lynch Syndrome carriers

First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma

First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

First-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes

First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer

First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

First-in-Human trial of DS9051b in participants with advanced solid tumors

First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

First-in-human Study to Test Safety and Anti-tumor Activity of a Novel Drug for Patients with Advanced Solid Tumor Harboring Genetic Alterations in MET

First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors

First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)

First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer (ES SCLC) (DeLLphi-303)

Follicle Stimulating Hormone Receptor T Cells

Fostamatinib 100 mg bid and Paclitaxel

Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)

Furmonertinib

G207

GB-4362

GB-5267 - IV only

GC4419

GCAR1

GCC2005

GDC-0084

GEN1042

GK01 Injection

GLA-SE

GLPG0187

GME751

GMX1777

GPC3 and/or TGFβ targeting CAR-T cells

GPC3-CAR-T cells

Frequently asked questions

Stay Ahead in Pharma